DJIA 16,943.81 28.74 0.17%
NASDAQ 4,415.49 19.29 0.44%
S&P 500 1,967.57 2.89 0.15%
market minute promo

Emergent BioSolutions (NYSE: EBS)

company name or ticker

You Shouldn't Ignore Gilead's Idelalisib

Gilead Sciences is widely known for its HIV drug portfolio and for its high-profile hep-C drug sofosbuvir. But it also has a potential winner with idelalisib, a blood cancer drug with a promising future.

Emergent BioSolutions to Webcast Presentation at Credit Suisse 2013 Healthcare Conference

Emergent BioSolutions to Release Third Quarter 2013 Financial Results and Conduct a Conference Call

Investing in Counteracting Biological and Chemical Agents

Biological and chemical agents are a lethal scourge of war, but Emergent Biosciences is developing countermeasures to a wide range of such agents.

Emergent Biosciences Finally Expanding Beyond Anthrax

Sector Update: Healthcare Shares Higher; eHealth Signs Agreement to Enroll Individuals

Sector Update: Healthcare

Emergent BioSolutions Appoints Barry Labinger as Executive Vice President of the Company and Preside

Emergent BioSolutions' CEO Discusses Q2 2013 Results - Earnings Call Transcript

Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2013